Novartis Historical Financial Ratios

NVS Stock

USD 94.36 1.79 1.93%

Novartis is lately reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 76.73 will help investors to properly organize and evaluate Novartis AG ADR financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

About Novartis Financial Ratios Analysis

Novartis AG ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novartis investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novartis financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novartis history.

Novartis Financial Ratios Chart

Novartis AG ADR financial ratios usually calculated using numerical values taken directly from Novartis financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Novartis. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.

At this time, Novartis' POCF Ratio is comparatively stable compared to the past year. Interest Coverage is likely to gain to 20.02 in 2024, whereas Dividend Yield is likely to drop 0.03 in 2024.

Price To Sales Ratio Dividend Yield Ptb Ratio Days Sales Outstanding

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Novartis AG ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novartis sales, a figure that is much harder to manipulate than other Novartis AG ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Novartis AG ADR dividend as a percentage of Novartis stock price. Novartis AG ADR dividend yield is a measure of Novartis stock productivity, which can be interpreted as interest rate earned on an Novartis investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most ratios from Novartis' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Novartis' POCF Ratio is comparatively stable compared to the past year. Interest Coverage is likely to gain to 20.02 in 2024, whereas Dividend Yield is likely to drop 0.03 in 2024.

	2022	2023	2024 (projected)
Dividend Yield	0.0401	0.0346	0.0254
Price To Sales Ratio	3.61	4.5	3.66

Dividend Yield Price To Sales Ratio

Novartis fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Invested Capital	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio
Price To Sales Ratio		-0.8	0.92	-0.16	-0.62	-0.82	0.51	-0.28	-0.24	-0.1	0.92	0.92	-0.22	0.16	-0.81	0.04	0.78	0.17	-0.24	0.01	0.28	0.82	0.11	-0.13	0.08	0.74
Dividend Yield	-0.8		-0.81	0.04	0.86	0.8	-0.24	0.72	0.39	0.41	-0.81	-0.57	0.65	-0.21	0.85	0.09	-0.88	-0.6	0.39	-0.04	0.04	-0.92	-0.33	0.37	0.08	-0.88
Ptb Ratio	0.92	-0.81		-0.13	-0.8	-0.64	0.48	-0.3	-0.28	-0.14	1.0	0.83	-0.19	0.24	-0.84	-0.06	0.86	0.3	-0.28	0.25	0.22	0.8	0.17	-0.17	0.23	0.69
Days Sales Outstanding	-0.16	0.04	-0.13		-0.07	0.2	0.1	-0.18	-0.39	0.35	-0.13	-0.25	-0.12	-0.3	-0.01	-0.13	0.01	0.21	-0.39	0.25	-0.36	-0.1	-0.32	0.02	0.27	-0.13
Book Value Per Share	-0.62	0.86	-0.8	-0.07		0.48	-0.23	0.68	0.42	0.32	-0.8	-0.4	0.56	-0.27	0.81	0.2	-0.89	-0.7	0.42	-0.37	0.13	-0.78	-0.34	0.33	-0.17	-0.71
Free Cash Flow Yield	-0.82	0.8	-0.64	0.2	0.48		-0.15	0.57	0.19	0.41	-0.64	-0.69	0.59	-0.01	0.69	0.03	-0.68	-0.33	0.19	0.37	-0.04	-0.86	-0.14	0.18	0.42	-0.87
Invested Capital	0.51	-0.24	0.48	0.1	-0.23	-0.15		0.29	-0.5	0.7	0.48	0.45	0.39	0.1	-0.52	0.28	0.34	-0.38	-0.5	0.24	0.4	0.07	-0.11	0.18	0.69	-0.07
Operating Cash Flow Per Share	-0.28	0.72	-0.3	-0.18	0.68	0.57	0.29		0.2	0.64	-0.3	-0.05	0.98	0.01	0.49	0.32	-0.61	-0.9	0.2	0.01	0.49	-0.74	-0.3	0.36	0.41	-0.79
Average Payables	-0.24	0.39	-0.28	-0.39	0.42	0.19	-0.5	0.2		-0.35	-0.28	0.09	0.15	-0.17	0.46	-0.42	-0.33	-0.04	1.0	0.16	0.03	-0.11	-0.11	0.31	-0.23	-0.07
Capex To Depreciation	-0.1	0.41	-0.14	0.35	0.32	0.41	0.7	0.64	-0.35		-0.14	-0.07	0.71	-0.11	0.11	0.3	-0.3	-0.68	-0.35	0.24	0.28	-0.55	-0.37	0.42	0.72	-0.66
Pb Ratio	0.92	-0.81	1.0	-0.13	-0.8	-0.64	0.48	-0.3	-0.28	-0.14		0.83	-0.19	0.24	-0.84	-0.06	0.86	0.3	-0.28	0.25	0.22	0.8	0.17	-0.17	0.23	0.69
Ev To Sales	0.92	-0.57	0.83	-0.25	-0.4	-0.69	0.45	-0.05	0.09	-0.07	0.83		0.0	0.07	-0.63	-0.05	0.61	0.01	0.09	0.08	0.34	0.7	-0.02	0.04	0.09	0.61
Free Cash Flow Per Share	-0.22	0.65	-0.19	-0.12	0.56	0.59	0.39	0.98	0.15	0.71	-0.19	0.0		0.05	0.39	0.28	-0.51	-0.85	0.15	0.19	0.52	-0.69	-0.28	0.38	0.58	-0.78
Roic	0.16	-0.21	0.24	-0.3	-0.27	-0.01	0.1	0.01	-0.17	-0.11	0.24	0.07	0.05		-0.29	0.63	0.29	0.12	-0.17	0.12	0.61	0.12	0.93	-0.6	0.19	0.09
Inventory Turnover	-0.81	0.85	-0.84	-0.01	0.81	0.69	-0.52	0.49	0.46	0.11	-0.84	-0.63	0.39	-0.29		-0.01	-0.96	-0.44	0.46	-0.17	-0.24	-0.79	-0.3	0.21	-0.18	-0.7
Net Income Per Share	0.04	0.09	-0.06	-0.13	0.2	0.03	0.28	0.32	-0.42	0.3	-0.06	-0.05	0.28	0.63	-0.01		-0.11	-0.38	-0.42	-0.42	0.53	-0.22	0.48	-0.59	0.03	-0.21
Days Of Inventory On Hand	0.78	-0.88	0.86	0.01	-0.89	-0.68	0.34	-0.61	-0.33	-0.3	0.86	0.61	-0.51	0.29	-0.96	-0.11		0.62	-0.33	0.25	0.13	0.88	0.35	-0.28	0.1	0.8
Payables Turnover	0.17	-0.6	0.3	0.21	-0.7	-0.33	-0.38	-0.9	-0.04	-0.68	0.3	0.01	-0.85	0.12	-0.44	-0.38	0.62		-0.04	0.22	-0.35	0.67	0.38	-0.4	-0.26	0.7
Average Inventory	-0.24	0.39	-0.28	-0.39	0.42	0.19	-0.5	0.2	1.0	-0.35	-0.28	0.09	0.15	-0.17	0.46	-0.42	-0.33	-0.04		0.16	0.03	-0.11	-0.11	0.31	-0.23	-0.07
Capex To Revenue	0.01	-0.04	0.25	0.25	-0.37	0.37	0.24	0.01	0.16	0.24	0.25	0.08	0.19	0.12	-0.17	-0.42	0.25	0.22	0.16		0.03	0.03	0.03	0.3	0.76	-0.11
Cash Per Share	0.28	0.04	0.22	-0.36	0.13	-0.04	0.4	0.49	0.03	0.28	0.22	0.34	0.52	0.61	-0.24	0.53	0.13	-0.35	0.03	0.03		-0.05	0.4	-0.05	0.35	-0.14
Pocfratio	0.82	-0.92	0.8	-0.1	-0.78	-0.86	0.07	-0.74	-0.11	-0.55	0.8	0.7	-0.69	0.12	-0.79	-0.22	0.88	0.67	-0.11	0.03	-0.05		0.27	-0.29	-0.24	0.98
Interest Coverage	0.11	-0.33	0.17	-0.32	-0.34	-0.14	-0.11	-0.3	-0.11	-0.37	0.17	-0.02	-0.28	0.93	-0.3	0.48	0.35	0.38	-0.11	0.03	0.4	0.27		-0.66	-0.06	0.28
Payout Ratio	-0.13	0.37	-0.17	0.02	0.33	0.18	0.18	0.36	0.31	0.42	-0.17	0.04	0.38	-0.6	0.21	-0.59	-0.28	-0.4	0.31	0.3	-0.05	-0.29	-0.66		0.31	-0.35
Capex To Operating Cash Flow	0.08	0.08	0.23	0.27	-0.17	0.42	0.69	0.41	-0.23	0.72	0.23	0.09	0.58	0.19	-0.18	0.03	0.1	-0.26	-0.23	0.76	0.35	-0.24	-0.06	0.31		-0.41
Pfcf Ratio	0.74	-0.88	0.69	-0.13	-0.71	-0.87	-0.07	-0.79	-0.07	-0.66	0.69	0.61	-0.78	0.09	-0.7	-0.21	0.8	0.7	-0.07	-0.11	-0.14	0.98	0.28	-0.35	-0.41

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	3.13	4.22	4.08	3.61	4.5	3.66
Dividend Yield	0.0324	0.0343	0.0397	0.0401	0.0346	0.0254
Ptb Ratio	3.7	3.6	2.74	3.16	4.49	3.07
Days Sales Outstanding	64.15	61.85	57.18	58.69	73.34	76.73
Book Value Per Share	24.22	24.86	30.17	27.21	22.47	17.72
Free Cash Flow Yield	0.0554	0.0544	0.0652	0.0618	0.0558	0.0494
Invested Capital	0.53	0.67	0.46	0.47	0.56	0.59
Operating Cash Flow Per Share	5.95	5.99	6.72	6.53	6.96	3.63
Stock Based Compensation To Revenue	0.0143	0.0156	0.0148	0.0159	0.0185	0.0195
Capex To Depreciation	(0.49)	(0.39)	(0.4)	(0.37)	(0.33)	(0.35)
Pb Ratio	3.7	3.6	2.74	3.16	4.49	3.07
Ev To Sales	4.59	4.65	3.86	4.01	4.77	2.82
Free Cash Flow Per Share	4.96	4.86	5.4	5.3	5.64	2.83
Roic	0.0673	0.0856	0.0876	0.25	0.0875	0.13
Inventory Turnover	2.41	2.12	2.38	2.16	2.11	1.82
Net Income Per Share	3.12	3.54	10.71	3.19	7.15	7.51
Days Of Inventory On Hand	151.36	172.13	153.34	169.11	173.05	184.62
Payables Turnover	2.66	2.8	2.86	3.01	2.53	4.03
Capex To Revenue	(0.0464)	(0.0518)	(0.0562)	(0.0515)	(0.059)	(0.062)
Cash Per Share	6.88	5.0	5.08	12.63	8.68	6.72
Pocfratio	15.06	14.91	12.32	13.15	14.51	14.92
Interest Coverage	10.69	11.68	33.23	10.99	11.43	20.02
Payout Ratio	0.93	0.87	0.31	1.08	0.49	0.42
Pfcf Ratio	18.06	18.39	15.34	16.19	17.92	19.28
Days Payables Outstanding	137.25	130.42	127.74	121.29	144.16	84.15
Income Quality	1.64	1.13	1.91	0.63	2.05	1.1
Roe	0.1	0.16	0.13	0.36	0.32	0.33
Ev To Operating Cash Flow	16.4	16.99	13.56	14.59	15.4	15.75
Pe Ratio	28.72	25.21	7.73	26.92	14.12	13.62
Ev To Free Cash Flow	19.66	20.96	16.88	17.96	19.03	20.35
Earnings Yield	0.0348	0.0397	0.13	0.0371	0.0708	0.0526
Net Debt To E B I T D A	1.17	1.65	0.57	1.25	0.7	0.47
Tangible Book Value Per Share	0.1	(4.45)	1.8	(0.7)	(1.67)	(1.59)
Receivables Turnover	5.69	5.9	6.38	6.22	4.98	4.26

Novartis Investors Sentiment

The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:

How To Invest In Novartis

Details

Is Novartis Stock a good investment?

Details

What is Novartis' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Commodity Directory Find actively traded commodities issued by global exchanges
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk

Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

4.987

Dividend Share

3.919

Earnings Share

4.1

Revenue Per Share

22.467

Quarterly Revenue Growth

0.074

The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Novartis Historical Financial Ratios

About Novartis Financial Ratios Analysis

Novartis Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ptb Ratio

Novartis fundamentals Correlations

Novartis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novartis fundamentals Accounts

Novartis Investors Sentiment

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novartis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Average Inventory	+ 1.0	Average Payables
Free Cash Flow Per Share	+ 0.98	Operating Cash Flow Per Share
Pfcf Ratio	+ 0.98	Pocfratio
Interest Coverage	+ 0.93	Roic
Ptb Ratio	+ 0.92	Price To Sales Ratio

Days Of Inventory On Hand	- 0.96	Inventory Turnover
Pocfratio	- 0.92	Dividend Yield
Payables Turnover	- 0.9	Operating Cash Flow Per Share
Days Of Inventory On Hand	- 0.89	Book Value Per Share
Pfcf Ratio	- 0.88	Dividend Yield
Days Of Inventory On Hand	- 0.88	Dividend Yield